US › Healthcare

ProMIS Neurosciences Inc. (PMN)

US · Healthcare · Biotechnology

$4.16+13.97%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-11.7M

EPS

$-1.28

EPS estimate

$-1.45

EPS came in at -1.28 against a street estimate of -1.45 — a beat of 11.7%.

Key statistics

Market cap

$32.7M

Forward P/E

0.0

P/B

0.64

Book value

$5.51

EPS (TTM)

$-11.65

52-week high

$27.40

52-week low

$2.78

50-day MA

$10.34

200-day MA

$12.80

Beta

-0.21

Analyst view

Analysts rate ProMIS Neurosciences Inc. a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $42.69.

Shareholding

Insiders

12.00%

Institutions

77.20%

Largest institutional holders

Fund	Stake
Jupiter Topco LLC	14.42%
Deep Track Capital, LP	9.32%
Wellington Management Company LLP	7.77%
Ally Bridge Group (NY) LLC	6.92%
Trails Edge Capital Partners, LP	6.21%
Woodline Partners LP	4.93%
Yu Fan	3.68%
Sphera Funds Management Ltd.	3.63%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ProMIS Neurosciences Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.